We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice.
- Authors
Hattori, Etsuko Yamamoto; Masuda, Tatsuya; Mineharu, Yohei; Mikami, Masamitsu; Terada, Yukinori; Matsui, Yasuzumi; Kubota, Hirohito; Matsuo, Hidemasa; Hirata, Masahiro; Kataoka, Tatsuki R.; Nakahata, Tatsutoshi; Ikeda, Shuji; Miyamoto, Susumu; Sugiyama, Hiroshi; Arakawa, Yoshiki; Kamikubo, Yasuhiko
- Abstract
Glioblastoma is the most common adult brain tumour, representing a high degree of malignancy. Transcription factors such as RUNX1 are believed to be involved in the malignancy of glioblastoma. RUNX1 functions as an oncogene or tumour suppressor gene with diverse target genes. Details of the effects of RUNX1 on the acquisition of malignancy in glioblastoma remain unclear. Here, we show that RUNX1 downregulates p21 by enhancing expressions of BIRC5 and PIF1, conferring anti-apoptotic properties on glioblastoma. A gene switch-off therapy using alkylating agent-conjugated pyrrole-imidazole polyamides, designed to fit the RUNX1 DNA groove, decreased expression levels of BIRC5 and PIF1 and induced apoptosis and cell cycle arrest via p21. The RUNX1-BIRC5/PIF1-p21 pathway appears to reflect refractory characteristics of glioblastoma and thus holds promise as a therapeutic target. RUNX gene switch-off therapy may represent a novel treatment for glioblastoma. Interfering with RUNX family proteins reduces glioblastoma growth in mice and reveals pathways involved in the maintenance of tumour growth.
- Subjects
GLIOBLASTOMA multiforme; RUNX proteins; BRAIN tumors; GENE therapy; TUMOR suppressor genes
- Publication
Communications Biology, 2022, Vol 5, Issue 1, p1
- ISSN
2399-3642
- Publication type
Article
- DOI
10.1038/s42003-022-03917-5